Résumé
This is an exceptional call issued by INCa to maintain the continuity of the CLIP² label for the Strasbourg Therapeutic Innovation Centre in Onco-Haematology (CITOHS), which was at risk following the dissolution of the GCS ICANS on 1 January 2026. The call is open exceptionally to former members of GCS ICANS and has an application deadline of 10 September 2026.
Analyse d'adéquation
This call is for therapeutic innovation in onco-hematology (cancer and blood disorders) and is restricted to former members of a specific French research consortium (GCS ICANS). Acme Corporation's focus on semiconductors, AI, and deep tech has no overlap with this medical research domain, and the company is not eligible as it is not a research institution or former consortium member.
Scores détaillés
Brief exécutif
LowPas d'analyse approfondie — ce score ≤ 6,0 n'a pas déclenché l'analyse détaillée. Voir l'analyse d'adéquation ci-dessus.
Description
La dissolution du GCS ICANS au 1er janvier 2026 a remis en cause la continuité de la labellisation CLIP² « Centre d'Innovation Thérapeutique en Onco-Hématologie de Strasbourg » (CITOHS), obtenue le 1er juillet 2024. Cet AAC est ouvert, à titre exceptionnel aux membres de l’ancien GGS ICANS....